GET DAILY SIGNALSGeneDx Holdings (WGS) Reports +11% Revenue Growth and Record Test Volumes in Q2 2026
Key Takeaways
- GeneDx reported total revenue of $114.4 million for the second quarter of 2026, up 11% year over year and above consensus estimates.
- Exome and genome test volume reached a record 30,785 tests, up 32% year over year, driving exome and genome revenue of $100.3 million (up 17%).
- The company returned to adjusted net income of $0.4 million, reaching profitability one quarter earlier than management had guided.
- On a GAAP (Generally Accepted Accounting Principles) basis, the company swung to a net loss of $17.7 million, or $0.60 per share.
- Adjusted EPS (earnings per share) of $0.01 beat the consensus estimate, which had called for a loss of $0.19 per share.
- Management reaffirmed full-year 2026 guidance, including $475–$490 million in revenue and at least 30% exome and genome volume growth.
Why These Results Matter
GeneDx Holdings Corp. focuses on exome and genome sequencing to diagnose rare diseases, so its quarterly numbers offer a useful read on adoption trends for genetic testing as a frontline tool. The second quarter of 2026 carried extra weight after the company had trimmed its full-year revenue outlook earlier, leaving investors looking for signs that demand was holding up. Record test volumes, a return to adjusted profitability, and reaffirmed guidance provided some reassurance. At the same time, the wider GAAP net loss underscored that scaling this type of business still involves real cost and reimbursement pressures. I also checked this using Tickeron’s AI Screener to compare performance against peers in the space.
The Quarter in Detail
GeneDx reported total revenue of $114.4 million for the second quarter of 2026, an 11% increase from $102.69 million in the prior-year period and above consensus estimates. Exome and genome revenue rose 17% year over year to $100.3 million, supported by a record 30,785 exome and genome tests, up 32%.
Gross margin improved to 70%, up from 69% in the first quarter. The company generated adjusted net income of $0.4 million, an $8.6 million sequential improvement that brought profitability back one quarter ahead of schedule. Adjusted EPS of $0.01 comfortably exceeded the consensus forecast for a loss of $0.19 per share.
On a GAAP basis, however, GeneDx reported a net loss of $17.7 million, or $0.60 per share, compared with net income of $10.81 million in the same quarter a year earlier. The blended average reimbursement rate (ARR) was $3,258 per test, roughly flat quarter over quarter. The company also expanded its debt facility by $50 million, bringing pro forma liquidity to about $188 million, and reaffirmed its full-year 2026 outlook.
How the Market Responded
Shares of WGS climbed following the second-quarter report, with traders responding positively to the earnings and revenue beats, the record test volume, and the earlier-than-expected return to adjusted profitability. Sentiment was also supported by management's decision to reaffirm full-year guidance, which eased concerns that the prior reduction in the revenue outlook signaled weakening demand. At the same time, the wider GAAP net loss and a blended average reimbursement rate that remained flat quarter over quarter kept some caution in the conversation, as investors weighed strong top-line momentum against ongoing cost and reimbursement headwinds.
What to Watch Going Forward
Looking ahead, investors will be watching whether GeneDx can sustain its volume growth while improving the economics of each test. The company has signaled that meaningful improvements in collection rates are expected in the fourth quarter of 2026 and into 2027, which makes reimbursement trends a central focus for future quarters.
Another area to monitor is the mix between exome and genome testing. Genome tests carry a lower collection rate today, so any shift in mix could influence both revenue growth and gross margin. Management's efforts to expand payer coverage, refine payer-specific workflows, and deploy AI-driven revenue cycle tools will be key to converting higher volumes into stronger reported profitability.
Finally, watch for continued traction in newer commercial channels such as general pediatrics and prenatal testing, which offer additional growth runway. With full-year 2026 guidance reaffirmed at $475–$490 million in revenue and at least 30% exome and genome volume growth, the balance between expansion and cost discipline will likely shape how the market evaluates the stock over the coming quarters. From what I see, these factors will determine whether the recent momentum holds.
Enhancing My Research with Tickeron Tools
I often turn to Tickeron’s AI Screener when reviewing earnings reports like this one. The tool lets me quickly filter stocks by technical patterns, fundamentals, and industry trends, which helps put a single company’s results into broader context without spending hours on manual screens. It has become a regular part of how I identify comparable names and spot potential follow-through opportunities after big data releases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WGS sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for WGS moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WGS's RSI Oscillator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where WGS advanced for three days, in 234 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
WGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WGS as a result. In 72 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for WGS turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
WGS moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for WGS crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for WGS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.481) is normal, around the industry mean (65.624). P/E Ratio (-16.876) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement